Marisa Cabeza, Araceli Sánchez-Márquez, Mariana Garrido, Aylín Silva and Eugene Bratoeff Pages 792 - 815 ( 24 )
This article summarizes the importance of different targets such as 5α-reductase, 17β-HSD, CYP17A, androgen receptor and protein kinase A for the treatment of prostate cancer and benign prostatic hyperplasia. It is a well known fact that dihydrotestosterone (DHT) is associated with the development of androgen-dependent afflictions. At the present time, several research groups are attempting to develop new steroidal and non-steroidal molecules with the purpose of inhibiting the synthesis and biological response of DHT. This review also discusses the most recent studies reported in the literature that describe the therapeutic potential of novel compounds, as well as the new drugs, principally inhibitors of 5α-reductase.
Benign prostatic hyperplasia, prostate cancer, 5-alpha reductase, 17-beta hydroxysteroid dehydrogenase, protein kinase A, androgen receptor, dehydroepiandrosterone derivatives, non-permeable testosterone conjugates, G proteins, PKA.
Departamento De Sistemas Biológicos, Universidad Autónoma Metropolitana- Xochimilco Calzada Del Hueso No. 1100, México, D.F., C.P. 04960, México.